Pancreatic Cancer Research

ResearcherCapital Medical UniversityActive in the last 2 years

Fei Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0532-9054; OpenAlex author ID A5100740269. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
31
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper

Papers 11

  1. Positive feedback regulation between glycolysis and histone lactylation drives oncogenesis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12943-024-02008-9↗
  2. Prognostic biomarkers of pancreatic cancer identified based on a competing endogenous RNA regulatory network. Last author DOI 10.21037/tcr-22-709↗
  3. Contrast-Enhanced Computed Tomography Does Not Provide More Information about Sarcopenia than Unenhanced Computed Tomography in Patients with Pancreatic Cancer. Co-author DOI 10.1155/2021/5546030↗
  4. Laparoscopic advanced intraoperative restaging for radiographic non-metastasis pancreatic cancer: Protocol for a single-center, cross-sectional and follow-up s… Last author DOI 10.1097/md.0000000000022090↗
  5. ELMO2 association with Gαi2 regulates pancreatic cancer cell chemotaxis and metastasis. Last author DOI 10.7717/peerj.8910↗
  6. Experts' consensus on intraoperative radiotherapy for pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.01.038↗
  7. Radical antegrade modular pancreatosplenectomy versus standard procedure in the treatment of left-sided pancreatic cancer: A systemic review and meta-analysis. Last author DOI 10.1186/s12893-017-0259-1↗
  8. Prognostic significance of positive peritoneal cytology in resectable pancreatic cancer: a systemic review and meta-analysis. Last author DOI 10.18632/oncotarget.14745↗
  9. Silencing pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer cells to gemcitabine. Co-author DOI 10.1007/s13277-015-4641-2↗
  10. HES 1 is essential for chemoresistance induced by stellate cells and is associated with poor prognosis in pancreatic cancer. Last author DOI 10.3892/or.2015.3789↗
  11. S-1 as monotherapy or in combination with leucovorin as second-line treatment in gemcitabine-refractory advanced pancreatic cancer: a randomized, open-label, m… Co-author DOI 10.1634/theoncologist.2014-0223↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Feng Cao · 4 shared papers, 2015–2022 · strength 0.42
  2. Ang Li · 3 shared papers, 2017–2020 · strength 0.36
  3. Tianpei Hong · 1 shared paper, 2024 · strength 0.21
  4. Rui Wei · 1 shared paper, 2024 · strength 0.21
  5. Wenzhe Si · 1 shared paper, 2024 · strength 0.21
  6. Yecheng Wang · 1 shared paper, 2020 · strength 0.19
  7. Yan Zhang · 1 shared paper, 2021 · strength 0.17
  8. Ang Li · 1 shared paper, 2021 · strength 0.17
  9. Zhi Zheng · 1 shared paper, 2020 · strength 0.16
  10. Wentong Mei · 1 shared paper, 2022 · strength 0.16
  11. Yixuan Ding · 1 shared paper, 2022 · strength 0.16
  12. Yuanxu Qu · 1 shared paper, 2022 · strength 0.16
  13. Yulin Guo · 1 shared paper, 2022 · strength 0.16
  14. Yuchen Jia · 1 shared paper, 2022 · strength 0.16
  15. Xu Che · 1 shared paper, 2019 · strength 0.08
  16. Shengping Li · 1 shared paper, 2019 · strength 0.08
  17. Jianwei Zhang · 1 shared paper, 2019 · strength 0.08
  18. Yingtai Chen · 1 shared paper, 2019 · strength 0.08
  19. Chengfeng Wang · 1 shared paper, 2019 · strength 0.08
  20. Jing Jin · 1 shared paper, 2019 · strength 0.08
  21. Ye‐Xiong Li · 1 shared paper, 2019 · strength 0.08
  22. Guang Li · 1 shared paper, 2019 · strength 0.08
  23. Menghua Dai · 1 shared paper, 2019 · strength 0.08
  24. Rufu Chen · 1 shared paper, 2019 · strength 0.08
  25. Lei Zheng · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.